Much has been said about the various applications of machine learning to drug discovery and the potential benefits. Yet despite ten years of hype, the true value remains hidden. In this talk, Lindsay Edwards (former VP of ML at both GSK and AZ and now CTO at Relation Therapeutics) discusses what may have gone wrong, and what the path forward may look like. This will include specific examples of applications of machine learning to both biology and chemistry, and some recent results from work at Relation.